Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

• Asıl Yazarlar: Xinghua Pang (Yazar), Zhaoliang Huang (Yazar), Tingting Zhong (Yazar), Peng Zhang (Yazar), Zhongmin Maxwell Wang (Yazar), Michelle Xia (Yazar), Baiyong Li (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

ABSTRACTClinical studies have shown that combination therapy of antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) significantly improves clinical benefit over PD-1 antibody alone. However, broad application of this combination has been limited by toxic...